Form 4: AEON Biopharma Insider Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)


Daewoong Co., Ltd reported changes in beneficial ownership of AEON Biopharma, Inc. common stock on October 30, 2026.

Summary

  • In-the-money derivative exercise: acquired 11,236,631 Class A Common Stock, $0.0001 par value per share at $0.00 ($1,124) on October 30, 2026; holds 23,188,345 after (Indirect).
  • Other acquisition/disposition: disposed of 3,822 Class A Common Stock, $0.0001 par value per share at $0.29 ($1,124) on October 30, 2026; holds 23,184,523 after (Indirect).
  • In-the-money derivative exercise: disposed of 11,236,631 Pre-Funded Warrant (right to buy) on October 30, 2026 (Indirect).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Daewoong Co., Ltd — 10% owner

DateTransactionSecuritySharesPriceValueHeld After
2026-10-30In-the-money derivative exerciseClass A Common Stock, $0.0001 par value per share11,236,631$0$1.1K23,188,345
2026-10-30Other acquisition/dispositionClass A Common Stock, $0.0001 par value per share3,822$0$1.1K23,184,523
2026-10-30In-the-money derivative exercisePre-Funded Warrant (right to buy)11,236,631——0

Key Dates

DateDescription
2026-10-30In-the-money derivative exercise (11,236,631 shares)
2026-10-30Other acquisition/disposition (3,822 shares)
2026-10-30In-the-money derivative exercise (11,236,631 shares)

Keywords

insider transaction, Form 4, AEON, AEON Biopharma, Inc., neutral, Daewoong Co., Ltd

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.